Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 15th Preview)
-
FDA grants first ctDNA MRD-guided bladder cancer adjuvant approval
The FDA approved Genentech’s Tecentriq (atezolizumab) and Tecentriq Hybreza as adjuvant therapy for muscle-invasive bladder cancer patients with circulating tumor DNA after cystectomy, using Natera’s Signatera CDx to guide treatment decisions. The decision represents the first FDA approval of a ctDNA MRD-guided therapy and the first authorization of a blood-based MRD assay as a CDx for this purpose. In IMvigor011, 250 patients who were ctDNA-positive by Signatera and had no radiographic evidence of disease were randomized to Tecentriq versus placebo. Disease-free survival was nearly doubled with Tecentriq (9.9 months vs. 4.8 months), and median overall survival was also longer (32.8 vs. 21.1 months).
-
Aardvark Therapeutics faces full FDA clinical hold on Prader-Willi drug program
Aardvark Therapeutics’ Prader-Willi syndrome program hit a major regulatory setback as the FDA placed a full clinical hold on ARD-101 and related studies. The hold follows a cardiovascular safety signal observed in a healthy-volunteer study at higher doses, prompting Aardvark to pause trials earlier this year and then expand the pause to additional candidates. In response, Aardvark said it will unblind data from its Phase 3 trial and open-label extension to support regulator and investigator review of the totality of efficacy and safety data. The company has already dosed 68 patients in the placebo-controlled Phase 3 study and 19 in the open-label extension, and it faces potential financing pressure as its cash runway tightens into mid-2027.
-
Regenxbio claims pivotal Duchenne gene therapy success and eyes FDA submission
Regenxbio reported that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, clearing the key milestone required to move toward an FDA submission. The company says the therapy produced sufficiently high levels of the miniaturized muscle protein target, supporting plans for regulatory filing with a goal of possible approval in 2027. The result arrives after heightened scrutiny across the DMD gene-therapy landscape, including prior safety concerns tied to competitor products. Regenxbio positioned its data as meeting the requirements for accelerated approval, framing the dataset as a step toward a potentially more favorable risk-benefit profile.
-
CREATE Medicines raises large Series B to scale in vivo CAR-T development
CREATE Medicines closed a $122 million Series B financing to advance its in vivo CAR-T platform across autoimmune disease and oncology. The company’s mRNA-LNP approach programs T cells, NK cells, and myeloid cells inside the body, aiming for repeat-dose and off-the-shelf potential without the logistics of traditional ex vivo CAR-T manufacturing. CREATE’s lead autoimmune program, CRT-402, is CD19-targeted and has shown deep, durable B-cell depletion in non-human primates. In oncology, the company reported early responses for its hepatocellular carcinoma program MT-303. It says it has dosed more than 50 patients across clinical programs to date.
-
FDA approval expands B-cell malignancy precision medicine with BeOne’s BCL2 inhibitor
BeOne Medicines won US accelerated approval for its sonrotoclax (BCL2 inhibitor) in a rare, aggressive blood cancer setting where Venclexta is used off-label. The regulatory move establishes BeOne’s position in the ongoing effort to broaden treatment options for patients with difficult-to-treat hematologic malignancies. The approval adds to the growing competitive pressure around BCL2-pathway targeting, as companies continue to refine patient selection and dosing strategies to achieve durable responses while managing safety tradeoffs.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.